Evelo Biosciences, Inc.

EVLO

US2997342025

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:58:14 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0495 ^USD	+8.32%		0.00%	-19.51%

Apr. 25	North American Morning Briefing : More Tech -2-	DJ
Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index

December 14, 2023 at 12:00 am EST

Latest news about Evelo Biosciences, Inc.

North American Morning Briefing : More Tech -2-	Apr. 25	DJ
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
North American Morning Briefing : Focus Turns to -2-	Apr. 04	DJ
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index	Dec. 14	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index	Dec. 11	CI
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Composite Index	Dec. 11	CI
Evelo Biosciences, Inc. Announces Marella Thorell Cease as Chief Financial Officer, Effective on December 1, 2023	Nov. 21	CI
Evelo Biosciences, Inc. Announces Simba Gill Ceases as Chief Executive Officer	Nov. 21	CI
Evelo Biosciences, Inc. Announces Executive Changes, Effective December 1, 2023	Nov. 21	CI
Evelo Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
TD Cowen Downgrades Evelo Biosciences to Market Perform From Outperform	23-10-18	MT
Sector Update: Health Care Stocks Retreat in Late Afternoon	23-10-17	MT
Sector Update: Health Care	23-10-17	MT
Top Midday Decliners	23-10-17	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	23-10-17	MT
Evelo Biosciences Says Phase 2 Trial of Psoriasis Treatment Did Not Meet Primary Endpoint; Shares Plunge Pre-Bell	23-10-17	MT
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis	23-10-17	CI
Medicenna Therapeutics Appoints Humphrey Gardner as Chief Medical Officer	23-10-10	MT
Evelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Morgan Stanley Adjusts Evelo Biosciences' Price Target to $10 From $2, Keeps Equalweight Rating	23-07-26	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	23-07-21	MT
Evelo Biosciences Signs Termination Agreement for Cambridge Office, Laboratory Space; Shares Up Premarket	23-07-21	MT
Evelo Biosciences Secures $25.5 Million in Private Placement	23-07-12	MT

Evelo Biosciences, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing a class of oral medicines that act on immune cells in the small intestine with systemic effects. It has built a platform to discover and develop oral medicines, which target the small intestinal axis (SINTAX). Its product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs). Its product candidate, EDP1815, is an investigational oral biologic being developed for the treatment of inflammatory diseases. EDP1815 is in clinical development for both psoriasis, driven largely by Th17 inflammation, and atopic dermatitis, driven by TH2 inflammation. EDP2939 is an investigational oral biologic consisting of EVs that it is developing for the potential treatment of inflammatory diseases. EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EVELO BIOSCIENCES, INC.	-19.51%	940K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs